Apparent Diffusion Coefficient of Glial Neoplasms: Correlation with Fluorodeoxyglucose–Positron-Emission Tomography and Gadolinium-Enhanced MR Imaging

References

1. 1.↵
   1. Burger PC,
   2. Vogel FS

   1. Burger PC,
   2. Vogel FS

   . The brain: tumors. In: Burger PC, Vogel FS eds. Surgical Pathology of the Central Nervous System and Its Coverings. New York: Wiley; 1982:223–66
2. 2.↵
   1. DeAngelis L

   . Brain tumors. N Engl J Med 2003;344:114–23

   CrossRef
3. 3.↵
   1. Hesselager G,
   2. Holland EC

   . Using mice to decipher the molecular genetics of brain tumors. Neurosurgery 2003;53:685–94

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Dai C,
   2. Holland EC

   . Astrocyte differentiation states and glioma formation. Cancer J 2003;9:72–81

   PubMedWeb of Science
5. 5.↵
   1. Fomchenko EI,
   2. Holland EC

   . Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 2006;12:5288–97

   Abstract/FREE Full Text
6. 6.↵
   1. Felix R,
   2. Schorner W,
   3. Laniado M,
   4. et al

   . Brain tumors: MR imaging with gadolinium-DTPA. Radiology 1985;156:681–88

   PubMedWeb of Science
7. 7.↵
   1. Brasch RC,
   2. Weinmann HJ,
   3. Wesbey GE

   . Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. AJR Am J Roentgenol 1984;142:625–30

   PubMedWeb of Science
8. 8.↵
   1. Warburg O

   . On the origin of cancer cells. Science 1956;123:309–14

   FREE Full Text
9. 9.↵
   1. Coleman RE,
   2. Hoffman JM,
   3. Hanson MW,
   4. et al

   . Clinical application of PET for the evaluation of brain tumors. J Nucl Med 1991;32:616–22

   Abstract/FREE Full Text
10. 10.↵
    1. Barker FG,
    2. Chang SM,
    3. Valk PE,
    4. et al

    . 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115–26

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Glantz MJ,
    2. Hoffman JM,
    3. Coleman RE,
    4. et al

    . Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 1991;29:347–55

    CrossRefPubMed
12. 12.↵
    1. Ishikawa M,
    2. Kikuchi H,
    3. Miyatake S,
    4. et al

    . Glucose consumption in recurrent gliomas. Neurosurgery 1993;33:28–33

    PubMedWeb of Science
13. 13.↵
    1. Kahn D,
    2. Follett KA,
    3. Bushnell DL,
    4. et al

    . Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 1994;163:1459–65

    CrossRefPubMed
14. 14.↵
    1. Doyle WK,
    2. Budinger TF,
    3. Valk PE,
    4. et al

    . Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987;11:563–70

    PubMed
15. 15.↵
    1. Buchpiguel CA,
    2. Alavi JB,
    3. Alavi A,
    4. et al

    . PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. J Nucl Med 1995;36:159–64

    Abstract/FREE Full Text
16. 16.↵
    1. Deshmukh A,
    2. Scott JA,
    3. Palmer EL,
    4. et al

    . Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. Clin Nucl Med 1996;21:720–25

    CrossRefPubMed
17. 17.↵
    1. Kim HS,
    2. Kim SY

    . A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol 2007;28:1693–99

    Abstract/FREE Full Text
18. 18.↵
    1. Sugahara T,
    2. Korogi Y,
    3. Kochi M

    . Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reason Imaging 1999;9:53–60

    CrossRef
19. 19.↵
    1. Higano S,
    2. Yun X,
    3. Kumabe T,
    4. et al

    . Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839–46

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Fan GG,
    2. Deng QL,
    3. Wu ZH,
    4. et al

    . Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a variable tool to predict tumour grading? Br J Radiol 2006;79:652–58

    Abstract/FREE Full Text
21. 21.↵
    1. Castillo M,
    2. Smith JK,
    3. Lester k,
    4. et al

    . Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 2001;22:60–64

    Abstract/FREE Full Text
22. 22.↵
    1. Kono K,
    2. Inoue Y,
    3. Nakayama K,
    4. et al

    . The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 2001;22:1081–88

    Abstract/FREE Full Text
23. 23.↵
    1. Lam WW,
    2. Poon WS,
    3. Metreweli C

    . Diffusion MR imaging in glioma: does it have any role in the pre-operation determination of grading of glioma? Clin Radiol 2002;57:219–25

    CrossRefPubMed
24. 24.↵
    1. Murakami R,
    2. Sugahara T,
    3. Nakamura H,
    4. et al

    . Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitive diffusion-weighted MR imaging. Radiology 2007;243:493–99

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Murakami R,
    2. Hirai T,
    3. Kitajima M,
    4. et al

    . Magnetic resonance imaging of pilocytic astrocytomas: usefulness of the minimum apparent diffusion coefficient (ADC) value for differentiation from high-grade gliomas. Acta Radiol 2008;49:462–67

    CrossRefPubMed
26. 26.↵
    1. Mori T,
    2. Nomori H,
    3. Ikeda K,
    4. et al

    . Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 2008;3:358–64

    CrossRefPubMed
27. 27.↵
    1. Ho KC,
    2. Lin G,
    3. Wang JJ,
    4. et al

    . Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging 2009;36:200–08. Epub 2008 Sep 9

    CrossRefPubMed
28. 28.↵
    1. Palumbo B,
    2. Angotti F,
    3. Marano GD

    . Relationship between PET-FDG and MRI apparent diffusion coefficients in brain tumors. Q J Nucl Med Mol Imaging 2008;52:1–6

    PubMed
29. 29.↵
    1. Le Bihan D,
    2. Breton E,
    3. Lallemand D,
    4. et al

    . Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1998;168:497–505
30. 30.↵
    1. Burdette JH,
    2. Elster AD,
    3. Ricci PE

    . Acute cerebral infarction: quantification of spin-density and T2 shine-through phenomena on diffusion-weighted MR images. Radiology 1999;212:333–39

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Collingnon F,
    2. Maes D,
    3. Delaere D,
    4. et al

    . Automated multi-modality image registration based on information theory. International Conference on Information Processing in Medical Imaging, IPMI 95, Ile de Berder, France, June 1995;263–74
32. 32.↵
    Minctracc. The McConnell Brain Imaging Centre of the Montreal Neurological Institute. http://www.bic.mni.mcgill.ca/ServicesSoftware/HomePage. Accessed January 25, 2010.
33. 33.↵
    1. Stadnik TW,
    2. Chaskis C,
    3. Michotte A,
    4. et al

    . Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 2001;22:969–76

    Abstract/FREE Full Text
34. 34.↵
    1. Rajendran JG,
    2. Mankoff DA,
    3. O'Sullivan F,
    4. et al

    . Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245–52

    Abstract/FREE Full Text
35. 35.↵
    1. Larson SM.

    . Positron emission tomography-based molecular imaging in human cancer: exploring the link between hypoxia and accelerated glucose metabolism. Clin Cancer Res 2004;10:2203–04

    FREE Full Text
36. 36.↵
    1. Mintorovitch J,
    2. Moseley ME,
    3. Chileuitt L,
    4. et al

    . Comparison of diffusion- and T2-weighted MRI for the early detection of cerebral ischemia and reperfusion in rats. Magn Reson Med 1991;18:39–50

    PubMedWeb of Science
37. 37.↵
    1. Moseley ME,
    2. Wendland MF,
    3. Kucharczyk J

    . Magnetic resonance imaging of diffusion and perfusion. Top Magn Reson Imaging 1991;3:50–67

    PubMed
38. 38.↵
    1. Warach S,
    2. Chien D,
    3. Li W,
    4. et al

    . Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology 1992;42:1717–22, Erratum in Neurology 1992;42:2192

    Abstract/FREE Full Text
39. 39.↵
    1. Warach S,
    2. Gaa J,
    3. Siewert B,
    4. et al

    . Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995;37:231–41

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Chenevert TL,
    2. McKeever PE,
    3. Ross BD

    . Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997;3:1457–66

    Abstract
41. 41.↵
    1. Valonen PK,
    2. Lehtimaki KK,
    3. Vaisanen TH,
    4. et al

    . Water diffusion in a rat glioma during ganciclovir-thymidine kinase gene therapy-induced programmed cell death in vivo: correlation with cell density. J Magn Reson Imaging 2004;19:389–96

    CrossRefPubMed
42. 42.↵
    1. Chenevert TL,
    2. Stegman LD,
    3. Taylor JM,
    4. et al

    . Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029–36

    Abstract/FREE Full Text
43. 43.↵
    1. Mardor Y,
    2. Roth Y,
    3. Lidar Z,
    4. et al

    . Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001;61:4971–73

    Abstract/FREE Full Text
44. 44.↵
    1. Hein PA,
    2. Eskey CJ,
    3. Dunn JF,
    4. et al

    . Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004;25:201–09

    Abstract/FREE Full Text
45. 45.↵
    1. Lidar Z,
    2. Mardor Y,
    3. Jonas T,
    4. et al

    . Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004;100:472–79

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Hamstra DA,
    2. Chenevert TL,
    3. Moffat BA,
    4. et al

    . Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005;102:16759–64

    Abstract/FREE Full Text
47. 47.↵
    1. Moffat BA,
    2. Chenevert TL,
    3. Lawrence TS,
    4. et al

    . Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524–29

    Abstract/FREE Full Text